PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.02.012 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Ludek Pour und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic. Hauptthemen laut MEDLINE: Multiple Myeloma, Cross-Over Studies. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
- Hematology Clinic, University Hospital "St. Marina," Medical University, Varna, Bulgaria.
- City Clinical Hospital #4 of Dnipro, Dnipro, Ukraine.
- Department of Hematology and Stem Cell Transplantation, National Institute for Hematology and Infectious Diseases, South Pest Central Hospital, Budapest, Hungary.
- Department of Internal Medicine and Hematology, Semmelweis University, Budapest, Hungary.
- Specialized Hospital for Active Treatment of Hematological Diseases, Sofia, Bulgaria.
Zitieren
APA
Pour, L., Micheva, I., Usenko, G., Mikala, G., Masszi, T., Simeonova, K., Thuresson, M., Huledal, G., Norin, S., Bakker, N. A., & Minarik, J. (2024). PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.02.012
Vancouver
Pour L, Micheva I, Usenko G, Mikala G, Masszi T, Simeonova K, et al. PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.02.012
BibTeX
@article{Pour2024,
author = {Pour, Ludek and Micheva, Ilina and Usenko, Ganna and Mikala, Gabor and Masszi, Tamas and Simeonova, Kameliya and Thuresson, Marcus and Huledal, Gunilla and Norin, Stefan and Bakker, Nicolaas A and Minarik, Jiri},
title = {PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.02.012}
}
EUVIMED